— BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders — BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending dose and food effects study — BMB-101 demonstrated central target engagement and…

Source

Previous articleFILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING OF UP TO C$2,000,000
Next articlePT425 – The Transformative Potential of Psychedelics, Community, and Live Music